2. Academic Validation
  3. Recapitulating primary immunodeficiencies with expanded potential stem cells: proof-of-concept with STAT1 gain-of-function

Recapitulating primary immunodeficiencies with expanded potential stem cells: proof-of-concept with STAT1 gain-of-function

  • J Allergy Clin Immunol. 2023 Dec 8:S0091-6749(23)02411-9. doi: 10.1016/j.jaci.2023.11.914.
Xueyan Liu 1,  Vera Sf Chan 2,  Kenneth Gc Smith 3,  Chang Ming 4,  Chung Sze Or 2,  Faria Tw Tsui 2,  Bo Gao 5,  Matthew C Cook 3,  Pentao Liu 6,  Chak Sing Lau 2,  Philip Hei Li 1
Affiliations

Affiliations

  • 1 Centre for Translational Stem Cell Biology, University of Hong Kong, Hong Kong; Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong. Electronic address: [email protected].
  • 2 Centre for Translational Stem Cell Biology, University of Hong Kong, Hong Kong; Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
  • 3 Department of Medicine, University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
  • 4 Centre for Translational Stem Cell Biology, University of Hong Kong, Hong Kong; School of Biomedical Sciences, University of Hong Kong, Hong Kong.
  • 5 Centre for Translational Stem Cell Biology, University of Hong Kong, Hong Kong; School of Biomedical Sciences, Chinese University of Hong Kong, Hong Kong.
  • 6 Centre for Translational Stem Cell Biology, University of Hong Kong, Hong Kong; School of Biomedical Sciences, University of Hong Kong, Hong Kong. Electronic address: [email protected].
PMID: 38072195 DOI: 10.1016/j.jaci.2023.11.914
Abstract

Background: Inborn errors of immunity (IEI) often lack specific disease models and personalized management. Signal transducer and activator of transcription (STAT)-1 gain-of-function (GoF) is such example of an IEI with diverse clinical phenotype with unclear pathomechanisms and unpredictable response to therapy. Limitations in obtaining fresh samples for functional testing and research further highlights the need for patient-specific ex-vivo platforms.

Objective: Using STAT1-GoF as an example IEI, we investigated the potential of patient-derived expanded potential stem cells (EPSC) as an ex-vivo platform for disease modelling and personalized treatment.

Methods: We generated EPSC derived from individual STAT1-GoF patients. STAT1 mutations were confirmed with Sanger sequencing. Functional testing including STAT1 phosphorylation/dephosphorylation and gene expression with or without Janus-kinase inhibitors (JAKi) were performed. Functional tests were repeated on EPSC lines with GoF mutations repaired by CRISPR/Cas9 editing.

Results: EPSC were successfully reprogrammed from STAT1-GoF patients and expressed the same pluripotent makers as controls, with distinct morphological differences. Patient-derived EPSC recapitulated the functional abnormalities of index STAT1-GoF patients with STAT1 hyperphosphorylation and increased expression of STAT1 and its downstream genes (IRF1, APOL6, and OAS1) following IFNγ stimulation. Addition of ruxolitinib and baricitinib inhibited STAT1 hyperactivation in STAT1-GoF EPSC in a dose-dependent manner, which was not observed with tofacitinib. Corrected STAT1 phosphorylation and downstream gene expression were observed among repaired STAT1-GoF EPSC cell lines.

Conclusion: This proof-of-concept study demonstrates the potential of our patient-derived EPSC platform toward modelling STAT1-GoF. We propose this platform toward researching, recapitulating and repairing other IEI in the future.

Keywords

Expanded Potential; Gain-of-Function; Gene editing; Immunodeficiency; Inborn errors of immunity; JAK inhibitor; Model; Personalized; STAT1; Stem cell.

Figures
Products